Vaccine plot thickens with new government study
The timing of today’s biggest autism story is worth noting after last week’s vaccine court settlement. Many news sites are publishing a Centers for Disease Control study that found no evidence of thimerosal, a mercury-based preservative used in most vaccines until 2001, increasing the risk of a child developing autism. The study joins several others over the last decade that reached the same conclusion.
Specifically, the study found that kids who were exposed to high levels through their own vaccinations or their mothers while pregnant, did not have a higher chance of receiving an autism diagnosis. The research used data for 1,000 U.S. children born from 1994 to 1999, about as recent as they can go with thimerosal no longer used in childhood vaccinations outside of the flu shot.
The article provides what is now a familiar background, citing the now-discredited Wakefield study of 1998 that caused parents to refrain from giving measles, mumps and rubella vaccines to their children, leading to outbreaks of all three diseases. Reuters (the outlet I’m deciphering for this story) also included a quick recap of the condition, including the scientific theory that autism is influenced by genes and the range of severity the disability inflicts on its inhabitants.
The story itself resembles many I’ve read before that also reported no link between anything related to vaccinations and autism, and odds suggest more stories will appear as the debate continues. The study is perhaps the best antidote the government could get at this moment, with the publication of last week’s settlement where the government conceded that vaccinations aggravated a child’s underlying conditions. Although they’re under the same umbrella, one item to note is the two stories dealing with two different branches of government. One dealt with the Court of Federal Claims under the judicial branch, while this story focuses on the CDC, a federal agency under the Department of Health and Human Services. The nature of studies would also render any conspiracy accusations ineffective, since five years of data was mined and analyzed. However, the data used should clarify the lengthy process that goes into studies, preventing factual compromises of the conclusions presented upon publication.
While the PR twist is the juiciest element upon examining the story, Reuters’ decision to recap autism again is interesting. Measuring the intelligence and memory capacity of an entire country is nearly impossible, but with news articles of any subject easily accessible online through a Google News search, combined with the coverage through traditional means, the question now could be how long does the absorption process take with topics previously unheard of. Autism has and will continue to be a complex, fascinating example, with news coverage on the subject not common until last decade. Autism’s ambiguity could also be a factor; there aren’t enough parallels to create “stereotypes.” Because no clear signals are present, knowing if and when other people encounter autistic people is extremely difficult.
As the government and other medical experts continue attempting to calm fears about vaccinations potentially harming kids, I’ll be paying attention to how many more times articles include the classic “introduction” of autism and its effects, as that will be the biggest indicator of how much knowledge the public has on the disability.